Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Immunol Res
Päätekijät: Blanco, Belén, Ramírez-Fernández, Ángel, Bueno, Clara, Argemí-Muntadas, Lidia, Fuentes, Patricia, Aguilar-Sopeña, Óscar, Gutierrez-Agüera, Francisco, Zanetti, Samanta Romina, Tapia-Galisteo, Antonio, Díez-Alonso, Laura, Segura-Tudela, Alejandro, Castellà, Maria, Marzal, Berta, Betriu, Sergi, Harwood, Seandean L., Compte, Marta, Lykkemark, Simon, Erce-Llamazares, Ainhoa, Rubio-Pérez, Laura, Jiménez-Reinoso, Anaïs, Domínguez-Alonso, Carmen, Neves, Maria, Morales, Pablo, Paz-Artal, Estela, Guedan, Sonia, Sanz, Laura, Toribio, María L., Roda-Navarro, Pedro, Juan, Manel, Menéndez, Pablo, Álvarez-Vallina, Luis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Association for Cancer Research 2022
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612571/
https://ncbi.nlm.nih.gov/pubmed/35362043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-21-0853
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia